How to Profit From the Drugstore Meltdown

[Intelligent Income Daily]( Welcome to Intelligent Income Daily, the free daily newsletter from wealth and income expert Brad Thomas. Brad’s experience spans three decades of real estate and stock market booms and busts. Today, he and his team focus exclusively on the safest and most predictable ways to earn sustainable and growing income in any market condition. You can find all past issues [here](. And if you have any questions, please contact Brad and his team [here](mailto:memberservices@widemoatresearch.com). How to Profit From the Drugstore Meltdown By Brad Thomas, Editor, Intelligent Income Daily The top three drugstores are having a meltdown. This Sunday, Rite Aid filed for Chapter 11 bankruptcy. And since the start of 2023, CVS shares dropped 16%. Walgreens fell 53%. And Rite Aid decreased by a massive 98%. Between all three, they have a combined total of 20,000 locations. For now… Many of these stores will soon be closing due to industry-wide pressures. Today I’ll walk through what those pressures are, each company’s particular issues, and point out which one of these drugstores is unfairly discounted… with every sign of bouncing back once Mr. Market returns to his senses. Recommended Link [NOW AIRING: We Just Inked a Deal with the World’s #1 Investor!]( [image]( Today, we have historic news to share with you. The world’s greatest living investor has officially joined us. Our firm has spent months pursuing a man widely considered the most successful investor throughout the history of our industry… though chances are, you’ve never even heard his name. And there’s a reason for that. He doesn’t need your money – or ours. He’s been fiercely private his entire life, wandering the world and doing exactly as he pleases by tapping [an extraordinary investment secret.]( Today, he’s airing the details for the first time ever. [Click here to see his full briefing.]( -- Drugstores’ Long List of Problems There are several pressures facing CVS, Walgreens, and Rite Aid that are industry-wide. First, e-commerce companies like Amazon have been buying into the business, offering online choices that compete with traditional drugstores. Next up, ever-expanding dollar stores also tend to stock the same basic items as drugstores… for less. And on top of all that, drugstores face billions in fines after losing the opioid death lawsuits levied against them. For those who haven’t been following these lawsuits filed in multiple states, they claim that drug manufacturers caused the opioid crisis through reckless marketing and understating risks… And that major pharmacies didn’t do enough to curb their illegal distribution. CVS agreed to pay $5 billion over 10 years in a settlement while Walgreens agreed to pay $5.7 billion over the course of 15 years. Rite Aid is only the latest and most well-known drugstore to file bankruptcy due to the opioid lawsuits. These fines are a lot of weight for any company to bear… especially one with too much debt and a clear lack of diversification. A Hard Look at Rite Aid and Walgreens So let’s start with the worst drugstore chain out of the top three, which is undoubtedly Rite Aid. The once-stable company has a rotten diagnosis that it’s trying to fix through bankruptcy. Reuters writes that, according to bankruptcy court filings, “Rite Aid has $4 billion in debt, $8.6 billion in liabilities, and $7.65 billion in assets.” It’s currently courting buyers for parts of its business, with at least one suitor expressing interest. Even so, Rite Aid isn’t doing well. And frankly, I want to stay far away from it, even at a “bargain” price. Walgreens is in far better shape, though that’s not saying much. It might not have filed for bankruptcy, but its CEO of less than three years, Rosalind Brewer, is stepping down. Apparently, she doesn’t feel like she can guide Walgreens through the industry’s issues. And this doesn’t bode well for its dividend. The company has increased its payout every year for 47 years now. But as I frequently say, the past is no guarantee of the future. The stock now yields nearly 9%, with a series of debt maturities due next year looming over it. That could be the catalyst for a dividend cut. And at Intelligent Income Daily, we avoid that kind of capital-killing event at all costs. Our goal is to steer you toward safe, income-generating opportunities… not into something that will lose us money. CVS Has Much More to Offer Investors Today Here’s why CVS has a much better shot at recovering from its bout of the share-price blues… For starters, the company is enormous and very well-placed. A whopping 85% of the U.S. population lives no more than 10 miles from a CVS drugstore. This gives it a great opportunity to further diversify into areas like healthcare services. I say “further,” because it already closed on an $8 billion buyout of Signify Health earlier this year. Signify is a healthcare platform that combines technology, analytics, and payments. Its network consists of 10,000+ clinicians in every U.S. state – all of who now work for CVS. And that’s on top of the insurance options CVS now offers. Better yet, the chain already has strong annual free-cash generation of $18 billion. This gives it plenty of room to continue paying its dividend – with its 3.5% yield – while still deleveraging from this year’s big purchase. It’s even been repurchasing shares, with a total of $14.5 billion authorized and $2 billion already bought back in Q2. Clearly, CVS isn’t worried about its future, industry headwinds and all. And neither am I. That’s why at a price around $71, I think CVS is a bargain. And with its competitors wiped out and left struggling, I believe we are going to see a major comeback from this particular drugstore chain. So if you want to capitalize on the drugstore meltdown… Now is your chance when shares are down. And if you’re looking for even more bargain opportunities, [check out our Intelligent Income Investor service]( While Amazon may be one of the factors cutting into the drugstore industry's profits, we have one play that’s cutting into Amazon’s massive profits. I call it the “Amazon Royalty” play. [You can check it out here.]( Happy SWAN (sleep well at night) investing, Brad Thomas Editor, Intelligent Income Daily IN CASE YOU MISSED IT… [Love him or hate him, Elon Musk is changing the AI game.]( Love him or hate him, there’s no doubt Elon Musk is a genius. He’s been called the Thomas Edison of our generation. Teeka Tiwari is the financial pioneer who has his eye on Musk’s latest venture. And that means it’s time to pay attention. Now Teeka’s research has taken him out to the world's hottest desert… To visit a relatively nondescript and unknown facility… That is supplying technology for Musk’s latest AI venture. Teeka believes this technology will trigger the biggest boom in history… All the while giving you, the early investor, a chance to completely transform your financial future. This investment could be bigger than Tesla… And bigger than SpaceX. In fact, he believes this AI stock has MORE upside potential than Nvidia has today. [Watch Teeka’s shocking new video here.]( [image]( [Wide Moat Research]( Wide Moat Research 55 NE 5th Avenue, Delray Beach, FL 33483 [www.widemoatresearch.com]( To ensure our emails continue reaching your inbox, please [add our email address]( to your address book. This editorial email containing advertisements was sent to {EMAIL} because you subscribed to this service. To stop receiving these emails, click [here](. Wide Moat Research welcomes your feedback and questions. But please note: The law prohibits us from giving personalized advice. To contact Customer Service, call toll free Domestic/International: 1-888-415-6046, Mon–Fri, 9am–5pm ET, or email us [here](mailto:feedback@widemoatresearch.com). © 2023 Wide Moat Research. All rights reserved. Any reproduction, copying, or redistribution of our content, in whole or in part, is prohibited without written permission from Wide Moat Research. [Privacy Policy]( | [Terms of Use](